Healthy Volunteers
Conditions
Brief summary
This is a single-center, open-label, fixed-sequence, Phase 1 study in healthy adult participants to evaluate the effect of AGMB-129 on the PK of a single dose of MDZ in healthy participants. A total of 14 participants will be enrolled and will receive study intervention in a fixed-sequence scheme. All IP will be administered orally and in fed conditions. The total duration of involvement for each participant, screening through follow-up, will be approximately 6 weeks.
Interventions
DRUGAGMB-129
Oral capsule
DRUGMDZ
Pre-filled oral syringes
Sponsors
Agomab Spain S.L.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: 1. Male or female, between 18 and 55 years old (extremes included) on the date of signing the ICF. 2. Body weight of at least 50.0 kg for men and 45.0 kg for women, and a body mass index (BMI) between 19.0 and 30.0 kg/m2 (extremes included) at screening. 3. Must be in good health based on medical history, physical examination, vital signs, and 12-lead ECG in the opinion of the investigator at screening. 4. Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must be ≤1.5x upper limit of normal (ULN) at screening. Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator. Note: Participants with diagnosed Gilbert's syndrome with total bilirubin \>1.5 ULN are eligible for the study if AST and ALT are ≤1.5x ULN. Key
Exclusion criteria
1. Known hypersensitivity to AGMB-129 ingredients or history of a significant allergic reaction to AGMB-129 ingredients as determined by the investigator. 2. Positive serology for hepatitis B virus surface antigen (HBsAg) or anti-hepatitis C virus \[HCV\] antibodies at screening, or history of hepatitis from any cause except for hepatitis A that was resolved at least 3 months prior to the first IP administration. 3. History of or a current immunosuppressive condition, including positive human immunodeficiency virus types 1 or 2 (HIV-1 \[2\]) antibodies at screening. 4. Current or history of vasculitis, valvular heart disease, or large vessel vascular disease (such as aneurism or dissection) at screening. 5. Any illness, judged by the investigator as clinically significant, in the 3 months prior to the first IP administration. 6. Presence or sequelae of gastrointestinal, liver, kidney (estimated glomerular filtration rate \[eGFR\] ≤80 mL/min/1.73 m² using the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs at screening. 7. History of malignancy within the past 5 years prior to screening, except for excised and curatively treated non-metastatic basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of cervix which is considered cured with minimal risk of recurrence. 8. History or presence of clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction, e.g., known long QT syndrome or a QT interval corrected for heart rate according to Fridericia's formula (QTcF) \>450 ms detected on the 12-lead ECG at screening or Day 1 predose. A first-degree atrioventricular block will not be considered as a clinically significant abnormality.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax for MDZ | Day 1 to Day 13 |
| Cmax for 1-OH-midazolam | Day 1 to Day 13 |
| AUC0-∞ for MDZ | Day 1 to Day 13 |
| AUC0-∞ for 1-OH-midazolam | Day 1 to Day 13 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC0-t for MET-154 | Day 3 to Day 14 | — |
| AUC0-t for MET-158 | Day 3 to Day 14 | — |
| AUC0-24 for AGMB-129 | Day 3 to Day 14 | — |
| AUC0-24 for MET-154 | Day 3 to Day 14 | — |
| Cmax for AGMB-129 | Day 3 to Day 14 | — |
| Number of participants with adverse events | From Screening to Day 15 | To evaluate the safety and tolerability of AGMB-129 in terms of adverse events at every visit |
| Number of participants with abnormal clinical laboratory values | From Screening to Day 15 | To evaluate the safety and tolerability of AGMB-129 in terms of abnormal laboratory parameters at every visit |
| Number of participants with abnormal vital signs | From Screening to Day 15 | To evaluate the safety and tolerability of AGMB-129 in terms of vital signs at every visit |
| Number of participants with abnormal physical exams | From Screening to Day 15 | To evaluate the safety and tolerability of AGMB-129 in terms of physical exams at every visit |
| AUC0-24 for MET-158 | Day 3 to Day 14 | — |
| Cmax for MET-154 | Day 3 to Day 14 | — |
| Cmax for MET-158 | Day 3 to Day 14 | — |
| AUC0-t for AGMB-129 | Day 3 to Day 14 | — |
Countries
Belgium
Outcome results
None listed